Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Autoimmune Disorders

Free Subscription Articles published in J Neuroimmunol Retrieve available abstracts of 231 articles: HTML format

Single Articles

April 2026
1. ALFONSO-CEDENO DF, Medina-Lozano L, Gaete PV, Quintero-Cusguen P, et al
   Bilateral optic neuritis preceding a Balo concentric sclerosis lesion: A case report and literature review.
   J Neuroimmunol. 2026;413:578874.
   PubMed     Abstract available
   
   
   March 2026
2. SIMONE K, Nathoo N, Hooper A, Aboseif A, et al
   Immature ovarian teratomas in anti-NMDA receptor encephalitis.
   J Neuroimmunol. 2026;412:578850.
   PubMed     Abstract available
   
   
   
3. MURAKAMI K, Tsujimoto H, Nakayama Y, Takeuchi H, et al
   The activation of classical and/or lectin complement pathway for the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy.
   J Neuroimmunol. 2026;412:578848.
   PubMed     Abstract available
   
   
   February 2026
4. LIU L, Lu D, Que W, Fan R, et al
   Docosahexaenoic acid supplementation aggravates myasthenia gravis through immune dysregulation.
   J Neuroimmunol. 2026;414:578889.
   PubMed     Abstract available
   
   
   
5. NAKASHIMA S, Sakuishi K, Hara M, Kawasaki R, et al
   Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome.
   J Neuroimmunol. 2026;414:578885.
   PubMed     Abstract available
   
   
   
6. PIEDRABUENA MA, Marrodan M, Zarate MA, Fiol M, et al
   Characterizing double seronegative neuromyelitis optica spectrum disorder: A distinct subgroup or part of the continuum?
   J Neuroimmunol. 2026;411:578822.
   PubMed     Abstract available
   
   
   
7. BOLDRINI V, Carnero Contentti E
   Limited availability of live CBA for AQP4-IgG testing and its consequences for the diagnosis and treatment of NMOSD in Latin American countries.
   J Neuroimmunol. 2026;411:578817.
   PubMed     Abstract available
   
   
   
8. BUNGANIC R, Revendova KZ, Hradilek P, Kusnierova P, et al
   Comparison of SIMOA and VEUS technologies for serum glial fibrillary acidic protein measurement.
   J Neuroimmunol. 2026;411:578825.
   PubMed     Abstract available
   
   
   
9. YASUDA M, Uzawa A, Ogaya E, Handa H, et al
   Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis.
   J Neuroimmunol. 2026;414:578876.
   PubMed     Abstract available
   
   
   January 2026
10. OSTROVSKY A, Simon AJ, Kaplan B
    Free light chains analysis in cerebrospinal fluid for the diagnosis of multiple sclerosis: A study in the Israeli population.
    J Neuroimmunol. 2026;413:578873.
    PubMed     Abstract available
    
    
    
11. LEI P, Lu Y, Xia J, Wang T, et al
    Efgartigimod for steroid-resistant autoimmune glial fibrillary acidic protein astrocytopathy: a case report and literature review.
    J Neuroimmunol. 2026;413:578866.
    PubMed     Abstract available
    
    
    
12. TANAKA K, Uzawa A, Yasuda M, Onishi Y, et al
    Serum from patients with acetylcholine receptor antibody-positive myasthenia gravis triggers pathogenic changes in human myotube cells.
    J Neuroimmunol. 2026;413:578871.
    PubMed     Abstract available
    
    
    
13. BIANCO A, Russo R, Cicia A, Marini S, et al
    Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review.
    J Neuroimmunol. 2026;410:578808.
    PubMed     Abstract available
    
    
    
14. RANIERI G, Chiarugi A, Buonvicino D
    Early exposure of NOD/ShiLtJ mice to Freund's adjuvant prompts delayed, spontaneous progressive encephalomyelitis.
    J Neuroimmunol. 2026;410:578809.
    PubMed     Abstract available
    
    
    
15. KWON YN, Ju W, Jeon JH, Hahm C, et al
    Clear-positive cut off determination of flow cytometric MOG-antibody assay in Korea: Alignment with international MOGAD diagnostic standards.
    J Neuroimmunol. 2026;410:578806.
    PubMed     Abstract available
    
    
    
16. HE R, Zhong Z, Feng H, Yao X, et al
    Efficacy and safety of intravenous efgartigimod for chronic inflammatory demyelinating polyneuropathy: A case series real-world study.
    J Neuroimmunol. 2026;410:578796.
    PubMed     Abstract available
    
    
    
17. PALMER AL, Wang R, Zonta YR, Bailey ZDJ, et al
    Cytokine and chemokine production by astrocytes is influenced by Cystatin C.
    J Neuroimmunol. 2026;410:578801.
    PubMed     Abstract available
    
    
    
18. MATSUYOSHI A, Shinoda K, Takeuchi H, Mizutani K, et al
    The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy.
    J Neuroimmunol. 2026;410:578799.
    PubMed     Abstract available
    
    
    
19. DEMPEGIOTI CA, Broumpoulis G, Brinia ME, Papadopoulos I, et al
    Advanced quantitative MRI reveals a unique pattern of metabolic alterations and iron-pathology linked to glial activation in Balo's concentric sclerosis.
    J Neuroimmunol. 2026;410:578798.
    PubMed     Abstract available
    
    
    
20. CURTIS K, Hendry E, Christensen Z, Aidukaitis B, et al
    Longitudinally-extensive transverse myelitis in the setting of recent Mycoplasma infection: Case series.
    J Neuroimmunol. 2026;410:578785.
    PubMed     Abstract available
    
    
    
21. SECHI E, Gastaldi M, Cortese R, Bisecco A, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management.
    J Neuroimmunol. 2026;410:578781.
    PubMed     Abstract available
    
    
    
22. KIMURA A, Takekoshi A, Miyazaki Y, Oh-Hashi K, et al
    TMEM132A autoimmunity in patients with suspected autoimmune cerebellar ataxia.
    J Neuroimmunol. 2026;413:578867.
    PubMed     Abstract available
    
    
    
23. ALEXAKI A, Baltoumas F, Tzanetakos D, Zografou C, et al
    B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.
    J Neuroimmunol. 2026;413:578854.
    PubMed     Abstract available
    
    
    December 2025
24. ABDELGAIED MY, Abdelgawad O, Rashad MH, Solayman MH, et al
    Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial.
    J Neuroimmunol. 2025;412:578852.
    PubMed     Abstract available
    
    
    
25. WON J, Kim J, Islam SMT, Qiao F, et al
    The potential role of S-nitrosoglutathione reductase in astrocyte BAFF expression and B cell activation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;412:578847.
    PubMed     Abstract available
    
    
    
26. MARRODAN M, Perez Arana CI, Kirchner RJ, Varela FJ, et al
    Anti-NMDAR encephalitis across the lifespan: Clinical, electrophysiological, and prognostic insights from a Latin American cohort.
    J Neuroimmunol. 2025;409:578766.
    PubMed     Abstract available
    
    
    
27. LUO H, Han Z, Yang J, Yang X, et al
    d-serine prevents cognitive impairment in a mouse model of NMDAR encephalitis.
    J Neuroimmunol. 2025;409:578768.
    PubMed     Abstract available
    
    
    
28. SIWAN E, Tungpoomjaruswong A, Merheb V, Lee FXZ, et al
    Live MOG-IgG cell-based assay: Comparison across flow cytometers and diagnostic validation on high-sensitivity full spectrum flow cytometry.
    J Neuroimmunol. 2025;409:578760.
    PubMed     Abstract available
    
    
    
29. ATASEVER U, Akunal C, Soyturk H
    Neuronal inflammation-associated biomarkers in cerebrospinal fluid of patients with acute and chronic inflammatory demyelinating polyneuropathies.
    J Neuroimmunol. 2025;409:578756.
    PubMed     Abstract available
    
    
    
30. KARIGOWDA L, Brown D, Wong C, Deshpande K, et al
    Bortezomib for the treatment of anti-N-methyl-d-aspartate receptor encephalitis in a patient with psoriatic arthritis receiving adalimumab: A case report and literature review.
    J Neuroimmunol. 2025;409:578754.
    PubMed     Abstract available
    
    
    
31. ULUC F, Ceylan D, Turkoglu SA
    Pilot analysis of Chitinase-3-like protein 1 and soluble Syndecan-1 CSF levels as potential biomarkers in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;411:578836.
    PubMed     Abstract available
    
    
    
32. LONG Q, Xie J, Yang Z, Zhang B, et al
    Personalized Ofatumumab therapy for autoimmune encephalitis: A case series of four patients.
    J Neuroimmunol. 2025;411:578835.
    PubMed     Abstract available
    
    
    November 2025
33. HAYASHI M
    Diversity of childhood-onset myasthenia gravis: pathophysiology and treatment.
    J Neuroimmunol. 2025;411:578803.
    PubMed     Abstract available
    
    
    
34. OREFICE NS, Amoriello R, Maghrebi O, Ballerini C, et al
    Early response in cytokine and miR-124a, -125b, -223 expression to anti-CD20 in Multiple Sclerosis and its animal model - a preliminary analysis.
    J Neuroimmunol. 2025;411:578823.
    PubMed     Abstract available
    
    
    
35. FOMINYKH V, Kovaleva I, Aksenova E, Kondrasheva E, et al
    Autoimmune encephalitis in first episode psychosis: Prospective non-interventional longitudinal study in tertiary psychiatric center.
    J Neuroimmunol. 2025;410:578815.
    PubMed     Abstract available
    
    
    
36. MIYAZAKI Y, Yokote H, Fujimori J, Sakurai K, et al
    Wearable-based physiological monitoring and brain magnetic resonance imaging metrics in multiple sclerosis: A feasibility study.
    J Neuroimmunol. 2025;410:578819.
    PubMed     Abstract available
    
    
    
37. MESSINA C
    IL-17 and IL-22 in Guillain-Barre syndrome: Untangling disease-specific signals from confounding factors.
    J Neuroimmunol. 2025;410:578820.
    PubMed    
    
    
    
38. VINCIGUERRA C, Montalbano G, Virzi V, Rini N, et al
    Psychopathology in myasthenia gravis: Results from a multicenter Italian study.
    J Neuroimmunol. 2025;410:578807.
    PubMed     Abstract available
    
    
    
39. CERRONI S, Hoshina Y, Glenn T, Goel N, et al
    Characteristics and prognosis of PCA-1 (anti-Yo) autoimmunity and the utility of the Brief Ataxia Rating Scale in a seropositive cerebellar ataxia cohort.
    J Neuroimmunol. 2025;410:578812.
    PubMed     Abstract available
    
    
    
40. ZHANG Y, Lv X, Wang Q, Ma X, et al
    Prior dexamethasone exposure attenuates the therapeutic efficacy of mouse bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis by fostering a hostile immunological microenvironment.
    J Neuroimmunol. 2025;410:578814.
    PubMed     Abstract available
    
    
    
41. JIA R, Yao X, Liu Q, Wang X, et al
    Identification of the core genes KLRB1 and RETN as potential shared diagnostic markers for major depressive disorder and systemic lupus erythematosus through bioinformatics and machine learning methodologies.
    J Neuroimmunol. 2025;410:578811.
    PubMed     Abstract available
    
    
    
42. ISHIHARA K, Naito H, Sugimoto T, Nakamori M, et al
    Comparison of prednisolone monotherapy vs. tacrolimus combination in NMOSD: Efficacy, safety, and optimal therapeutic timing.
    J Neuroimmunol. 2025;408:578737.
    PubMed     Abstract available
    
    
    
43. MAROTTA C, Rolla E, Fabris M, Domenis R, et al
    Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy.
    J Neuroimmunol. 2025;410:578805.
    PubMed     Abstract available
    
    
    
44. GOLGE BF, Sarikaya C, Bingol CA, Aktekin B, et al
    Autoimmune encephalitis following bevacizumab therapy in ovarian carcinoma: A case report and review.
    J Neuroimmunol. 2025;410:578804.
    PubMed     Abstract available
    
    
    October 2025
45. DAGHLAS I, Pluvinage JV, Gill D
    Genetically reduced MTHFR activity confers protection against multiple sclerosis.
    J Neuroimmunol. 2025;410:578784.
    PubMed     Abstract available
    
    
    
46. DEMIR UNAL E
    A Neuroimmunological Axis between systemic autoimmunity and Parkinson's disease following long-COVID: A case series.
    J Neuroimmunol. 2025;410:578795.
    PubMed     Abstract available
    
    
    
47. YU M, Zhang N, Chen C, He Y, et al
    Inflammatory ratios as early predictors of disease severity and immunotherapy response in autoimmune encephalitis.
    J Neuroimmunol. 2025;410:578786.
    PubMed     Abstract available
    
    
    
48. DITLEVSEN REGEN E, Victor D, Hendrikx T
    Neoehrlichiosis in patients with multiple sclerosis in Halmstad, Sweden: A case series.
    J Neuroimmunol. 2025;410:578787.
    PubMed     Abstract available
    
    
    
49. GE F, Song B, Wang X, Tian M, et al
    Association of thyroid autoimmune status with Alzheimer's disease biomarkers in euthyroid subjects.
    J Neuroimmunol. 2025;409:578780.
    PubMed     Abstract available
    
    
    
50. HOSHINA Y, Liu S, Wright MA, Delic A, et al
    Prolonged corticosteroid therapy and steroid-sparing maintenance immunotherapy lower relapse risk in pediatric and adult MOGAD.
    J Neuroimmunol. 2025;407:578709.
    PubMed     Abstract available
    
    
    
51. MORAES BF, Sucupira JCL, Junior MGO, Leite GAPD, et al
    When gut and nerves collide: A case of Neuromyelitis Optica Spectrum disorder after golimumab for ulcerative colitis.
    J Neuroimmunol. 2025;407:578700.
    PubMed     Abstract available
    
    
    
52. SEN S, Kurtuncu M, Demir S, Gunduz T, et al
    Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD).
    J Neuroimmunol. 2025;407:578686.
    PubMed     Abstract available
    
    
    
53. ZHANG Z, Chen K, Qiu H, Ke S, et al
    GD3 antibody subtyping reveals central-peripheral dichotomy in autoimmune neurological disorders.
    J Neuroimmunol. 2025;409:578771.
    PubMed     Abstract available
    
    
    
54. KUNATH N, Ramfjord HAB, Kvisvik EV, Konyves-Kolonics M, et al
    ITPR1 autoantibody-associated autoimmunity as a cause of newly emerging cognitive decline mimicking Alzheimer's disease: Case report and brief review of the literature.
    J Neuroimmunol. 2025;409:578774.
    PubMed     Abstract available
    
    
    
55. NATHOO N, Neyal N, Son J, Schwarz CG, et al
    The hidden toll: Atrophy of key central nervous system relays in African American women with multiple sclerosis.
    J Neuroimmunol. 2025;409:578776.
    PubMed     Abstract available
    
    
    September 2025
56. GOUZOUASIS V, Tsifintaris M, Tastsoglou S, Markoglou N, et al
    Epstein-Barr virus reactivation is associated with altered immune cell profiles in peripheral blood and cerebrospinal fluid of treatment-naive multiple sclerosis patients.
    J Neuroimmunol. 2025;409:578758.
    PubMed     Abstract available
    
    
    
57. MANN GS, Nandwani S, Jain N
    Microscopic Polyangiitis With a Twist: A Rare Case of CRAO and Brainstem Infarction.
    J Neuroimmunol. 2025;406:578685.
    PubMed     Abstract available
    
    
    
58. ARLT FA, Majed M, Wu J, Zekeridou A, et al
    N-type voltage-gated calcium channel antibody testing lacks diagnostic value in Lambert-Eaton myasthenic syndrome.
    J Neuroimmunol. 2025;406:578681.
    PubMed     Abstract available
    
    
    
59. ZHANG LJ, Qi Y, Sun CY, Yang L, et al
    Tumefactive demyelination as the first presentation of MOG ab-associated disease.
    J Neuroimmunol. 2025;406:578653.
    PubMed     Abstract available
    
    
    
60. LIU A, Lucas MC, Kazerooni L, Yousuf MM, et al
    Reversal of profound cortical atrophy with immunotherapy in pediatric anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2025;406:578649.
    PubMed     Abstract available
    
    
    
61. IYENGAR ARS, Dunkley PR, Dickson PW
    Immunity in Parkinson's disease - the role of adaptive and auto-immune responses and gut-microbiome axis.
    J Neuroimmunol. 2025;409:578755.
    PubMed     Abstract available
    
    
    
62. HANSEN MM, El Mahdaoui S, Hansen MB, Hvalkof VH, et al
    Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.
    J Neuroimmunol. 2025;409:578751.
    PubMed     Abstract available
    
    
    
63. MARTINEZ-MEDINA S, Olivas-Dominguez ER, Romero-Armenta RN, Avalos-Arias A, et al
    PERM associated with thymic carcinoma with triple-autoantibody positivity: case report and literature review.
    J Neuroimmunol. 2025;409:578753.
    PubMed     Abstract available
    
    
    August 2025
64. XU XN, Luo WJ, Li HN, Li X, et al
    Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.
    J Neuroimmunol. 2025;409:578741.
    PubMed     Abstract available
    
    
    
65. KIMURA A, Takekoshi A, Maekawa Y, Tanaka K, et al
    Serum neurofilament light chain as a prognostic biomarker of glial fibrillary acidic protein autoimmunity.
    J Neuroimmunol. 2025;408:578739.
    PubMed     Abstract available
    
    
    
66. ZHAO M, Li J, Jin L, Luo Z, et al
    Next-generation approaches in autoimmune encephalitis diagnosis: A multi-omics perspective.
    J Neuroimmunol. 2025;408:578740.
    PubMed     Abstract available
    
    
    
67. TANG Y, Wang H, Wang X, Yan Z, et al
    Characterizing the relationship between FLAIR hyper-rim lesions and paramagnetic rim lesions in multiple sclerosis.
    J Neuroimmunol. 2025;408:578738.
    PubMed     Abstract available
    
    
    
68. TANAKA K, Uzawa A, Yasuda M, Onishi Y, et al
    Serum from patients with MuSK antibody-positive myasthenia gravis triggers transcriptomic changes leading to muscle atrophy and weakness in human myotube cells.
    J Neuroimmunol. 2025;408:578735.
    PubMed     Abstract available
    
    
    
69. TOMIZAWA Y, Okada H, Miyachi M, Hoshino Y, et al
    Apathy in autoimmune GFAP Astrocytopathy: A case series and literature review.
    J Neuroimmunol. 2025;408:578733.
    PubMed     Abstract available
    
    
    
70. HOSHINA Y, Smith TL, Mstat AD, Wong KH, et al
    An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote.
    J Neuroimmunol. 2025;405:578651.
    PubMed     Abstract available
    
    
    
71. MIYAKE S, Katsura Y, Baba M, Tomizawa-Shinohara H, et al
    Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.
    J Neuroimmunol. 2025;405:578644.
    PubMed     Abstract available
    
    
    
72. IQBAL A, Mubarak B, Amar A, Mukhtar S, et al
    Association of interleukins 17A and 22 levels and their common genetic polymorphisms in Guillain Barre syndrome.
    J Neuroimmunol. 2025;408:578721.
    PubMed     Abstract available
    
    
    
73. EL-WAHSH S, Ramanathan S, Reddel S
    Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis.
    J Neuroimmunol. 2025;407:578718.
    PubMed     Abstract available
    
    
    
74. FAN T, Jiang Y, Hu W, Xu W, et al
    Efficacy of FcRn antagonist efgartigimod in the treatment of Miller-Fisher/Guillain-Barre overlap syndrome: Two case reports.
    J Neuroimmunol. 2025;407:578712.
    PubMed     Abstract available
    
    
    
75. BICIMVEREN MS, Ciftci SN, Alp G
    A rare cause of visual impairment in patients with multiple sclerosis: Uveitis.
    J Neuroimmunol. 2025;407:578714.
    PubMed     Abstract available
    
    
    July 2025
76. YANG C, Jiang X, Cheng Z, Zheng C, et al
    Neuroprotective effects of Analgecine by modifying cholesterol metabolism in EAE mice model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578704.
    PubMed     Abstract available
    
    
    
77. SAXENA S, Zhirova A, Krishnan R, Healy B, et al
    SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
    J Neuroimmunol. 2025;407:578694.
    PubMed     Abstract available
    
    
    
78. LAUTEN TH, Reed EC, Natour T, Pitts LJ, et al
    Beta adrenergic signaling as a therapeutic target for autoimmunity.
    J Neuroimmunol. 2025;407:578705.
    PubMed     Abstract available
    
    
    
79. AKOWUAH PK, Botchway E, Owusu E, Ohene DA, et al
    Are corneal nerve and dendritic cell parameters assessed via corneal confocal microscopy good markers for multiple sclerosis? - A systematic review and meta-analysis.
    J Neuroimmunol. 2025;407:578697.
    PubMed     Abstract available
    
    
    
80. GOMEZ FP, Bake S, Young CR, Sohrabji F, et al
    Therapeutic effects of estrogens on inflammatory demyelination in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578698.
    PubMed     Abstract available
    
    
    
81. KAUR G, Kumari P, Devi P, Swaminathan A, et al
    Gut dysbiosis influences the pathophysiology of multiple sclerosis: A case-control study from North India.
    J Neuroimmunol. 2025;407:578696.
    PubMed     Abstract available
    
    
    
82. INOUE Y, Fujii T, Kashu KY, Watanabe M, et al
    Associations between serum levels of alpha-calcitonin gene-related peptide and clinical features of neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2025;404:578615.
    PubMed     Abstract available
    
    
    
83. SANDWEISS AJ, Rosen J, Aduru C, Chandrasekar A, et al
    MOGAD optic neuritis after mild head/orbital trauma in six children.
    J Neuroimmunol. 2025;404:578605.
    PubMed     Abstract available
    
    
    
84. JAHANSOOZ JR, Kameoka AM, Shibuya J, Abramowitz J, et al
    Recurrent anti-NMDA receptor encephalitis in first-trimester pregnancy with initially antibody-negative CSF.
    J Neuroimmunol. 2025;404:578602.
    PubMed     Abstract available
    
    
    June 2025
85. WELSH NC, DiSano KD, Pike SC, Linzey M, et al
    Network analysis of intrathecally synthesized proteins to unravel mechanisms of disease course in multiple sclerosis.
    J Neuroimmunol. 2025;406:578678.
    PubMed     Abstract available
    
    
    
86. NIBBER A, Wills B, Pettingill P, Fox H, et al
    Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis.
    J Neuroimmunol. 2025;406:578671.
    PubMed     Abstract available
    
    
    
87. WON J, Kim J, Qiao F, Singh AK, et al
    Therapeutic potential of S-nitrosoglutathione reductase inhibitor in B cell-driven experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;406:578673.
    PubMed     Abstract available
    
    
    
88. NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al
    Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity.
    J Neuroimmunol. 2025;406:578672.
    PubMed     Abstract available
    
    
    
89. PEREIRA DA, Mariano M, Marcon N, Maia MM, et al
    A rare neuroendocrine presentation in pediatric anti-glutamic acid decarboxylase autoimmunity: Case report and literature review.
    J Neuroimmunol. 2025;406:578670.
    PubMed     Abstract available
    
    
    
90. CAKAN M, Demirel E, Cimen B, Ozen NPA, et al
    Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience.
    J Neuroimmunol. 2025;403:578591.
    PubMed     Abstract available
    
    
    
91. ABBOUD H, Steingo B, Vargas D, Patel J, et al
    Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series.
    J Neuroimmunol. 2025;403:578585.
    PubMed     Abstract available
    
    
    
92. ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al
    Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888 eQTLs.
    J Neuroimmunol. 2025;406:578666.
    PubMed     Abstract available
    
    
    
93. JOHNSON CB, Fehmi J, Rinaldi S
    The immunology and neuropathology of the autoimmune nodopathies.
    J Neuroimmunol. 2025;406:578665.
    PubMed     Abstract available
    
    
    
94. SAGHARICHI M, Aalipour MA, Eghbal E, Javandoust Gharehbagh F, et al
    Autoimmune encephalitis and delayed diagnosis in common variable immunodeficiency: A case report and review of literature.
    J Neuroimmunol. 2025;406:578662.
    PubMed     Abstract available
    
    
    May 2025
95. WEIGEL J, Appeltshauser L, Sommer C, Doppler K, et al
    Proprioceptive endings at muscle spindles as a possible target of autoantibodies.
    J Neuroimmunol. 2025;405:578648.
    PubMed     Abstract available
    
    
    
96. YAO ZY
    Reflections on the influence of seasonal and environmental factors in myasthenia gravis.
    J Neuroimmunol. 2025;405:578645.
    PubMed    
    
    
    
97. MAKHARIA A, Agarwal A, Garg D, Garg A, et al
    The dilemma of demyelination: A case of Schilder's disease with insights from literature.
    J Neuroimmunol. 2025;402:578584.
    PubMed     Abstract available
    
    
    
98. WANG Y, Huan X, Song J, Zhu X, et al
    Clinical outcome and peripheral CD4(+) T profile in impending myasthenic crisis: A prospective cohort study.
    J Neuroimmunol. 2025;402:578572.
    PubMed     Abstract available
    
    
    April 2025
99. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus generate a unique B cell population" [Journal of Neuroimmunology volume 394 (2024) 578408].
    J Neuroimmunol. 2025;404:578625.
    PubMed    
    
    
    
100. ONISHI Y, Uzawa A, Yasuda M, Akamine H, et al
     Elevated serum levels of IL-10 family and IL-12 family cytokines in myasthenia gravis.
     J Neuroimmunol. 2025;404:578621.
     PubMed     Abstract available
     
     
     
101. MASI F, Al Qudsi S, Visigalli D, Zardini E, et al
     Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
     J Neuroimmunol. 2025;404:578622.
     PubMed     Abstract available
     
     
     
102. NAGAPPA M, Mondal S, Rajeevan S, Pradeepkumar B, et al
     Exploring the role of altered oxi-inflammasome activity in the immunobiology of inflammatory neuropathies.
     J Neuroimmunol. 2025;401:578556.
     PubMed     Abstract available
     
     
     
103. LI Q, Liu B, Guan Y, Wang Y, et al
     Double filtration plasmapheresis in autoimmune gastritis with subacute combined degeneration of the spinal cord: A case report.
     J Neuroimmunol. 2025;403:578618.
     PubMed     Abstract available
     
     
     
104. ZHARIKOV Y, Shitova A, Melnikova P, Voloshin I, et al
     Autoantibody-mediated disorders of the central and peripheral nervous system: Overview Infection.
     J Neuroimmunol. 2025;403:578616.
     PubMed     Abstract available
     
     
     
105. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
     Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
     J Neuroimmunol. 2025;403:578607.
     PubMed    
     
     
     
106. PETROU P, Kassis I, Levi Y, Yaghmour N, et al
     Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).
     J Neuroimmunol. 2025;403:578613.
     PubMed     Abstract available
     
     
     
107. TRAN GT, Bedi S, Rakesh P, Verma ND, et al
     Autoantigen and IL-2 activated CD4(+)CD25(+)T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis.
     J Neuroimmunol. 2025;404:578611.
     PubMed     Abstract available
     
     
     
108. ZHANG Z, Wu J, Xu D, Zhao S, et al
     Clinical characteristics and immunotherapy efficacy in autoimmune-associated benign epilepsy with centrotemporal spikes: A prospective cohort study.
     J Neuroimmunol. 2025;404:578603.
     PubMed     Abstract available
     
     
     
109. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
     Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
     J Neuroimmunol. 2025;404:578606.
     PubMed     Abstract available
     
     
     
110. STAYKOVA M, Bruestle A
     Nitric oxide and experimental autoimmune encephalomyelitis review.
     J Neuroimmunol. 2025;404:578586.
     PubMed     Abstract available
     
     
     March 2025
111. WANG Z, Du X, Wang Q, Zhang Y, et al
     Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report.
     J Neuroimmunol. 2025;403:578590.
     PubMed     Abstract available
     
     
     
112. ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al
     Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.
     J Neuroimmunol. 2025;403:578589.
     PubMed     Abstract available
     
     
     
113. CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al
     Endocrine disrupting chemicals in early MS disease activity.
     J Neuroimmunol. 2025;400:578546.
     PubMed     Abstract available
     
     
     February 2025
114. KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al
     Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naive individuals with multiple sclerosis.
     J Neuroimmunol. 2025;401:578571.
     PubMed     Abstract available
     
     
     
115. SHAHBAKHSH M, Jalousian F, Hosseini SH, Naser Moghadasi A, et al
     Toxocara canis-originated recombinant C-type lectin improves the disability scores of experimental autoimmune encephalomyelitis in murine in vivo models.
     J Neuroimmunol. 2025;402:578569.
     PubMed     Abstract available
     
     
     
116. KUO PC, Zhao Z, Scofield BA, Paraiso HC, et al
     Benzoylacetonitrile as a novel anti-inflammatory compound on attenuating microglia and encephalitogenic T cell activation in experimental autoimmune encephalomyelitis.
     J Neuroimmunol. 2025;401:578557.
     PubMed     Abstract available
     
     
     
117. HE D, Zhou Y, Zhang Y, Zhang J, et al
     Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.
     J Neuroimmunol. 2025;401:578558.
     PubMed     Abstract available
     
     
     
118. GHOSH S, Bhaskar R, Singh KK, Sinha JK, et al
     Immunotherapy challenges and potential role of unclassified antibodies in complex autoimmune encephalitis.
     J Neuroimmunol. 2025;401:578555.
     PubMed    
     
     
     
119. LIU Y, Sun H, Xu Y, Xuan B, et al
     Identification and characteristics of a novel CD8alphaalpha T cell subset in a refractory myasthenia gravis patient.
     J Neuroimmunol. 2025;400:578551.
     PubMed     Abstract available
     
     
     
120. ZHANG M, Zhu X, Yu L, Fang Z, et al
     Pediatric anti-CaValpha2delta autoimmune encephalitis: A case report and literature review.
     J Neuroimmunol. 2025;401:578550.
     PubMed     Abstract available
     
     
     
121. YAN Z, Yang X, Lin B, Zhu Q, et al
     Brain network alteration was associated with 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis.
     J Neuroimmunol. 2025;400:578549.
     PubMed     Abstract available
     
     
     
122. CULINA S, Commere PH, Turc E, Jouy A, et al
     MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis subjects determined by small RNA-sequencing.
     J Neuroimmunol. 2025;401:578531.
     PubMed     Abstract available
     
     
     January 2025
123. RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al
     Targeting extracellular matrix components to attenuate microglia neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple sclerosis.
     J Neuroimmunol. 2025;400:578533.
     PubMed     Abstract available
     
     
     
124. FALK KK, Cabrera LA, Junker R, Leypoldt F, et al
     Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis.
     J Neuroimmunol. 2025;400:578528.
     PubMed     Abstract available
     
     
     
125. ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al
     Balo concentric sclerosis, an emerging variant of multiple sclerosis: A case-series and literature review.
     J Neuroimmunol. 2025;400:578527.
     PubMed     Abstract available
     
     
     
126. LI Y, Chen P, Huang X, Huang H, et al
     Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].
     J Neuroimmunol. 2025 Jan 16:578526. doi: 10.1016/j.jneuroim.2025.578526.
     PubMed    
     
     
     
127. VORASOOT N, Halfdanarson TR, Madigan NN, Dubey D, et al
     Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy.
     J Neuroimmunol. 2025;398:578485.
     PubMed     Abstract available
     
     
     
128. GULEC B, Everest E, Uygunoglu U
     Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple sclerosis, a case report".
     J Neuroimmunol. 2025;399:578523.
     PubMed    
     
     
     
129. FALSO S, Zara P, Marini S, Puci M, et al
     Seasonal variation in myasthenia gravis incidence.
     J Neuroimmunol. 2025;399:578524.
     PubMed     Abstract available
     
     
     December 2024
130. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
     Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
     J Neuroimmunol. 2024;399:578519.
     PubMed    
     
     
     
131. ITOH C, Swart G, St Louis E, Gandhi M, et al
     IgLON5 autoimmunity secondary to immune checkpoint inhibitor.
     J Neuroimmunol. 2024;399:578516.
     PubMed     Abstract available
     
     
     
132. HERNANDEZ RUIZ JJ, Romero Malacara AMC, Lopez Mota LA, Perez Guzman MJ, et al
     Therapeutic development towards T follicular helper cells as a molecular target in myasthenia gravis disease.
     J Neuroimmunol. 2024;399:578503.
     PubMed     Abstract available
     
     
     
133. LIANG Y, Huang J, Zhang X, Xu F, et al
     Quantitative assessment of thalamic damage and serum neurofilament light chain in relapsing-remitting multiple sclerosis.
     J Neuroimmunol. 2024;399:578504.
     PubMed     Abstract available
     
     
     
134. GILLIGAN M, O'Donnell L, Westbrook A, Tubridy N, et al
     A complex and severe encephalitis associated with four co-existing neuronal cell-surface autoantibodies.
     J Neuroimmunol. 2024;399:578501.
     PubMed     Abstract available
     
     
     
135. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
     Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.
     J Neuroimmunol. 2024;399:578502.
     PubMed     Abstract available
     
     
     November 2024
136. OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al
     Retinoic acid modulates peripheral blood helper innate lymphoid cell composition in vitro in patients with multiple sclerosis.
     J Neuroimmunol. 2024;398:578489.
     PubMed     Abstract available
     
     
     
137. KIM S, Lee S, Chung YH, Ju H, et al
     Myelin oligodendrocyte glycoprotein antibody-associated disease with histopathologic features of primary CNS angiitis without demyelination: Case report and literature review.
     J Neuroimmunol. 2024;396:578467.
     PubMed     Abstract available
     
     
     
138. LAI R, Wu Z, Wang H, Feng L, et al
     Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series.
     J Neuroimmunol. 2024;396:578458.
     PubMed     Abstract available
     
     
     October 2024
139. FAN Z, Li J, Zhang Y, Kang J, et al
     Kidney injury: An overlooked manifestation in autoimmune encephalitis.
     J Neuroimmunol. 2024;397:578472.
     PubMed     Abstract available
     
     
     
140. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
     Corrigendum to "Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology 385 (2023) 578241].
     J Neuroimmunol. 2024;397:578465.
     PubMed    
     
     
     
141. CHENG X, Cui C, Shen S, Li Z, et al
     Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2024;395:578422.
     PubMed     Abstract available
     
     
     
142. HONG Y, Gao L, Huang SQ, Liu S, et al
     Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series.
     J Neuroimmunol. 2024;395:578431.
     PubMed     Abstract available
     
     
     
143. LI Y, Chen P, Huang X, Huang H, et al
     Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.
     J Neuroimmunol. 2024;396:578464.
     PubMed     Abstract available
     
     
     September 2024
144. LIU Y, Yang CL, Zhao XL, Zhao YJ, et al
     Characteristics of anti-contactin1 antibody positive autoimmune nodopathies combined with membranous nephropathy.
     J Neuroimmunol. 2024;396:578460.
     PubMed     Abstract available
     
     
     
145. BAI G, Bai Y, Guan H, Ren H, et al
     A case report of lymphoproliferative disease in brain following therapies with mycophenolate Mofetil and Fingolimod and literature review.
     J Neuroimmunol. 2024;394:578410.
     PubMed     Abstract available
     
     
     
146. YASUDA M, Uzawa A, Onishi Y, Handa H, et al
     Elevated serum levels of C-terminal agrin fragment in acetylcholine receptor antibody-positive myasthenia gravis.
     J Neuroimmunol. 2024;396:578455.
     PubMed     Abstract available
     
     
     
147. BAXTER L, Hopkins S, O'Connor KC, Pham MC, et al
     Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy.
     J Neuroimmunol. 2024;396:578454.
     PubMed     Abstract available
     
     
     
148. HUANG YF, Briggs CM, Gokhale S, Punga AR, et al
     Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients.
     J Neuroimmunol. 2024;396:578447.
     PubMed     Abstract available
     
     
     
149. SAMIM MM, Mandal R, Joy J, Dhar D, et al
     Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The SANMAD Study.
     J Neuroimmunol. 2024;396:578446.
     PubMed     Abstract available
     
     
     
150. XU Y, Wei Y, Shi Z, Yin F, et al
     Multimodal magnetic resonance longitudinal study on the deep gray matter in multiple sclerosis patients with teriflunomide.
     J Neuroimmunol. 2024;396:578445.
     PubMed     Abstract available
     
     
     August 2024
151. ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al
     Discordance of reported multiple sclerosis clinical course amongst patients and providers.
     J Neuroimmunol. 2024;395:578443.
     PubMed     Abstract available
     
     
     
152. BILEK F, Ercan Z, Deniz G, Ozgul S, et al
     High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
     J Neuroimmunol. 2024;395:578434.
     PubMed     Abstract available
     
     
     
153. CHEN P, Chen J, Huang H, Liu W, et al
     Conventional dendritic cells are more activated in the hyperplastic Thymus of myasthenia gravis patients.
     J Neuroimmunol. 2024;395:578441.
     PubMed     Abstract available
     
     
     
154. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
     Authors' response to letter to the editor: Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis.
     J Neuroimmunol. 2024;393:578405.
     PubMed    
     
     
     
155. KRIEGER S, Zarif M, Bumstead B, Buhse M, et al
     Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort.
     J Neuroimmunol. 2024;393:578397.
     PubMed     Abstract available
     
     
     
156. SHARMA M, Pal P, Gupta SK, Potdar MB, et al
     Microglial-mediated immune mechanisms in autoimmune uveitis: Elucidating pathogenic pathways and targeted therapeutics.
     J Neuroimmunol. 2024;395:578433.
     PubMed     Abstract available
     
     
     
157. LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al
     Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and cerebrospinal fluid in multiple sclerosis.
     J Neuroimmunol. 2024;395:578432.
     PubMed     Abstract available
     
     
     
158. YARIMI JM, Sandweiss AJ, Salazar KP, Massrey C, et al
     IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: A case report.
     J Neuroimmunol. 2024;395:578430.
     PubMed     Abstract available
     
     
     
159. ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al
     TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible new entity.
     J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429.
     PubMed    
     
     
     
160. TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al
     Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
     J Neuroimmunol. 2024;394:578428.
     PubMed     Abstract available
     
     
     July 2024
161. LI YJ, Zhang XY, Zhang WJ, Han YL, et al
     Proteomics analysis of immune response-related proteins in Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
     J Neuroimmunol. 2024;394:578423.
     PubMed     Abstract available
     
     
     
162. WUERCH EC, Mirzaei R, Yong VW
     Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
     J Neuroimmunol. 2024;394:578421.
     PubMed     Abstract available
     
     
     
163. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
     Novel model of multiple sclerosis induced by EBV-like virus generates a unique B cell population.
     J Neuroimmunol. 2024;394:578408.
     PubMed     Abstract available
     
     
     
164. YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al
     Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.
     J Neuroimmunol. 2024;394:578407.
     PubMed     Abstract available
     
     
     
165. PEGAT A, Chanson JB, Lozeron P, Joubert B, et al
     Identification of rare variants in the FBXO38 gene of patients with chronic inflammatory demyelinating polyradiculoneuropathy.
     J Neuroimmunol. 2024;392:578381.
     PubMed     Abstract available
     
     
     
166. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
     Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A retrospective cohort and scoping review of literature.
     J Neuroimmunol. 2024;392:578369.
     PubMed     Abstract available
     
     
     
167. FONSECA A, Santos E, Taipa R
     Balo concentric sclerosis: Literature review and report of two cases.
     J Neuroimmunol. 2024;392:578370.
     PubMed     Abstract available
     
     
     June 2024
168. LI Y, Yi JS, Guptill JT, Juel VC, et al
     Immune dysregulation in chronic inflammatory demyelinating polyneuropathy.
     J Neuroimmunol. 2024;391:578360.
     PubMed     Abstract available
     
     
     
169. RECHTMAN A, Zveik O, Haham N, Brill L, et al
     A protective effect of lower MHC-II expression in MOGAD.
     J Neuroimmunol. 2024;391:578351.
     PubMed     Abstract available
     
     
     
170. WHEELER D, Bezih M, Lannen N
     Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
     J Neuroimmunol. 2024;393:578385.
     PubMed    
     
     
     
171. YONG HYF, Batty NJ, Tottenham I, Koch M, et al
     Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?
     J Neuroimmunol. 2024;393:578384.
     PubMed    
     
     
     May 2024
172. SRIRAM S, Kim KW, Ljunggren-Rose A
     Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
     J Neuroimmunol. 2024;392:578371.
     PubMed     Abstract available
     
     
     
173. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
     As time goes by: Treatment challenges in elderly people with multiple sclerosis.
     J Neuroimmunol. 2024;391:578368.
     PubMed     Abstract available
     
     
     
174. CARVER JJ, Pugh BA, Lau KM, Didonna A, et al
     Lipid metabolism is dysregulated in endocrine glands upon autoimmune demyelination.
     J Neuroimmunol. 2024;391:578366.
     PubMed     Abstract available
     
     
     April 2024
175. LI S, Sun D, Wang R, Du Q, et al
     Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
     J Neuroimmunol. 2024;391:578352.
     PubMed    
     
     
     
176. DAMMAN S, Sukpornchairak P, Ahituv A, Chen A, et al
     Unilateral cortical autoimmune encephalitis: A case series and comparison to late-onset Rasmussen's encephalitis.
     J Neuroimmunol. 2024;391:578350.
     PubMed     Abstract available
     
     
     
177. MIN YG, Ju W, Sung JJ
     Superior oblique palsy as the initial manifestation of anti-contactin-1 IgG4 autoimmune nodopathy: A case report.
     J Neuroimmunol. 2024;391:578348.
     PubMed     Abstract available
     
     
     
178. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
     Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
     J Neuroimmunol. 2024;390:578347.
     PubMed     Abstract available
     
     
     
179. MUNZ C
     Altered EBV specific immune control in multiple sclerosis.
     J Neuroimmunol. 2024;390:578343.
     PubMed     Abstract available
     
     
     March 2024
180. LUO W, Wang X, Kong L, Chen H, et al
     Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
     J Neuroimmunol. 2024;388:578263.
     PubMed     Abstract available
     
     
     
181. KATSU M, Sekine-Tanaka M, Tanaka M, Horai Y, et al
     Inhibition of repulsive guidance molecule-a ameliorates compromised blood-spinal cord barrier integrity associated with neuromyelitis optica in rats.
     J Neuroimmunol. 2024;388:578297.
     PubMed     Abstract available
     
     
     
182. HAHAM N, Zveik O, Rechtman A, Brill L, et al
     Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
     J Neuroimmunol. 2024;388:578289.
     PubMed     Abstract available
     
     
     
183. DE ALMEIDA GMR, de Araujo RS, Castrillo BB, Silva GD, et al
     Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
     J Neuroimmunol. 2024;388:578295.
     PubMed     Abstract available
     
     
     
184. CHANG EH, Hardy TA
     Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
     J Neuroimmunol. 2024;389:578330.
     PubMed     Abstract available
     
     
     
185. FOGEL A, Olcer M, Goel A, Feng X, et al
     Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
     J Neuroimmunol. 2024;389:578328.
     PubMed     Abstract available
     
     
     February 2024
186. KMEZIC I, Press R, Glenewinkel H, Doppler K, et al
     Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
     J Neuroimmunol. 2024;389:578326.
     PubMed     Abstract available
     
     
     
187. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
     Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
     J Neuroimmunol. 2024;390:578315.
     PubMed     Abstract available
     
     
     
188. ZHANG C, Liu R, Gao B, Li T, et al
     Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2024;387:578285.
     PubMed     Abstract available
     
     
     
189. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
     Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
     J Neuroimmunol. 2024;387:578286.
     PubMed     Abstract available
     
     
     
190. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
     EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
     J Neuroimmunol. 2024;389:578314.
     PubMed     Abstract available
     
     
     
191. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
     Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
     J Neuroimmunol. 2024;389:578313.
     PubMed     Abstract available
     
     
     
192. LI X, Chen JJ, Hur M, Paton GR, et al
     Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.
     J Neuroimmunol. 2024;388:578312.
     PubMed     Abstract available
     
     
     
193. TIAN J, Liu X, Liang H, Shen Y, et al
     Expression of lymphocyte activation gene-3 on CD4(+)T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
     J Neuroimmunol. 2024;388:578308.
     PubMed     Abstract available
     
     
     
194. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
     Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
     J Neuroimmunol. 2024;388:578299.
     PubMed     Abstract available
     
     
     January 2024
195. THAKOLWIBOON S, Linnoila J, Pittock SJ, Dubey D, et al
     Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.
     J Neuroimmunol. 2024;387:578293.
     PubMed     Abstract available
     
     
     
196. WADI L, Mandge V
     Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A case series.
     J Neuroimmunol. 2024;386:578271.
     PubMed     Abstract available
     
     
     
197. CERNE D, Losa M, Mattioli P, Lechiara A, et al
     Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword.
     J Neuroimmunol. 2024;387:578291.
     PubMed     Abstract available
     
     
     
198. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
     Dysregulated autotaxin expression by T cells in multiple sclerosis.
     J Neuroimmunol. 2024;387:578282.
     PubMed     Abstract available
     
     
     
199. FUJIMORI J, Nakashima I
     Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
     J Neuroimmunol. 2024;387:578280.
     PubMed     Abstract available
     
     
     December 2023
200. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
     Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
     J Neuroimmunol. 2023;387:578268.
     PubMed     Abstract available
     
     
     
201. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
     Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
     J Neuroimmunol. 2023;387:578270.
     PubMed     Abstract available
     
     
     
202. LI HY, Xia M, Song M, Xie Y, et al
     Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.
     J Neuroimmunol. 2023;387:578269.
     PubMed     Abstract available
     
     
     
203. HU B, Dang G, Chen S, Li S, et al
     Neuromyelitis optica spectrum disorder mimicking stroke: A case report and literature review.
     J Neuroimmunol. 2023;385:578223.
     PubMed     Abstract available
     
     
     
204. MIYAZAWA R, Fujimori J, Atobe Y, Nakashima I, et al
     CSF CXCL13 is elevated in patients with CIDP and may reflect higher disease activity.
     J Neuroimmunol. 2023;385:578238.
     PubMed     Abstract available
     
     
     
205. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
     Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
     J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
     PubMed     Abstract available
     
     
     November 2023
206. CHEN Y, Wan W, Yao X, Guan Y, et al
     Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
     J Neuroimmunol. 2023;385:578245.
     PubMed     Abstract available
     
     
     
207. LOWE MC, Money KM, Matthews E, Pastula DM, et al
     case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal fluid.
     J Neuroimmunol. 2023;385:578249.
     PubMed     Abstract available
     
     
     
208. CAO B, Li Q, Xiong L, Ruan H, et al
     Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.
     J Neuroimmunol. 2023;384:578221.
     PubMed     Abstract available
     
     
     
209. LI Y, Liu Y, Zhao W, An X, et al
     Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2023;384:578218.
     PubMed     Abstract available
     
     
     
210. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
     Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
     J Neuroimmunol. 2023;385:578241.
     PubMed     Abstract available
     
     
     
211. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
     Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
     J Neuroimmunol. 2023;385:578240.
     PubMed     Abstract available
     
     
     October 2023
212. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
     Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
     J Neuroimmunol. 2023;385:578226.
     PubMed     Abstract available
     
     
     
213. MOORE L, Munir A, Bae S, Miller J, et al
     Transverse myelitis associated with Mpox infection.
     J Neuroimmunol. 2023;383:578190.
     PubMed     Abstract available
     
     
     
214. KORAL G, Ulusoy C, Cossins J, Lazaridis K, et al
     Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
     J Neuroimmunol. 2023;383:578195.
     PubMed     Abstract available
     
     
     
215. RASHED HR, Niu Z, Dyck PJ, Dyck PJB, et al
     Nerve transcriptomes in autoimmune and genetic demyelinating neuropathies: Pathogenic pathway assessment of nerve demyelination.
     J Neuroimmunol. 2023;384:578220.
     PubMed     Abstract available
     
     
     
216. KIM KW, Ljunggren-Rose A, Matta P, Toki S, et al
     Inhibition of SUMOylation promotes remyelination and reduces IL-17 mediated autoimmune inflammation: Novel approach toward treatment of inflammatory CNS demyelinating disease.
     J Neuroimmunol. 2023;384:578219.
     PubMed     Abstract available
     
     
     September 2023
217. DOMINGUEZ L, McKeon A, Tobin WO, Lopez-Chiriboga S, et al
     Long term outcomes in patients with anti-DPPX autoimmunity.
     J Neuroimmunol. 2023;384:578214.
     PubMed     Abstract available
     
     
     
218. HOLM-YILDIZ S, Dysgaard T, Krag T, Pedersen BS, et al
     Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
     J Neuroimmunol. 2023;384:578215.
     PubMed     Abstract available
     
     
     
219. YASUDA M, Uzawa A, Ozawa Y, Kojima Y, et al
     Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies.
     J Neuroimmunol. 2023;384:578205.
     PubMed     Abstract available
     
     
     
220. CHENG X, Li Y, Wang Y, Sun Y, et al
     Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis.
     J Neuroimmunol. 2023;383:578203.
     PubMed     Abstract available
     
     
     
221. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
     Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
     J Neuroimmunol. 2023;383:578202.
     PubMed     Abstract available
     
     
     
222. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
     Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
     J Neuroimmunol. 2023;384:578200.
     PubMed     Abstract available
     
     
     
223. MICHAEL MR, Wieske L, Koel-Simmelink MJ, van Schaik IN, et al
     Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.
     J Neuroimmunol. 2023;382:578169.
     PubMed     Abstract available
     
     
     
224. YAMAHARA N, Yoshikura N, Takekoshi A, Kimura A, et al
     Anti-N-methyl-d-aspartate receptor encephalitis preceded by meningitis lasting up to 60 days.
     J Neuroimmunol. 2023;382:578173.
     PubMed     Abstract available
     
     
     
225. NI J, Liu X, Zhang R, Wang H, et al
     Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
     J Neuroimmunol. 2023;382:578166.
     PubMed     Abstract available
     
     
     
226. HUANG Z, Liu Y, An X, Zhang C, et al
     Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2023;382:578167.
     PubMed     Abstract available
     
     
     
227. ERLEBACH R, Brandi G
     Effect and timing of operative treatment for teratoma associated N-Methyl-d-Aspartate receptor-antibody encephalitis: A systematic review with meta-analysis.
     J Neuroimmunol. 2023;382:578153.
     PubMed     Abstract available
     
     
     
228. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
     Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
     J Neuroimmunol. 2023;383:578199.
     PubMed     Abstract available
     
     
     
229. PERDAENS O, van Pesch V
     MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
     J Neuroimmunol. 2023;386:578196.
     PubMed     Abstract available
     
     
     August 2023
230. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
     Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
     J Neuroimmunol. 2023;383:578178.
     PubMed     Abstract available
     
     
     
231. TERRIM S, Silva GD, de Sa E Benevides Falcao FC, Dos Reis Pereira C, et al
     Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis.
     J Neuroimmunol. 2023;381:578140.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum